Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

American Journal of Hematology

Volumn 89, Issue 2, 2014, Pages 145-150

  Katodritou, Eirini ^a   Terpos, Evangelos ^b   Kelaidi, Charikleia ^c   Kotsopoulou, Maria ^d   Delimpasi, Sossana ^e   Kyrtsonis, Marie Christine ^b   Symeonidis, Argiris ^f   Giannakoulas, Nikos ^g   Stefanoudaki, Aikaterini ^e   Christoulas, Dimitrios ^h   Chatziaggelidou, Christina ^a   Gastari, Vassiliki ^a   Spyridis, Nikos ^a   Verrou, Evgenia ^a   Konstantinidou, Pavlina ^a   Zervas, Kostas ^a   Dimopoulos, Meletios A ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c G PAPANICOLAOU HOSPITAL   (Greece)

^d General Anticancer Hospital Metaxa   (Greece)

^e KAT HOSPITAL   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g UNIVERSITY OF THESSALY   (Greece)

^h 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MIDDLE AGED; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PLASMA CELL LEUKEMIA; PRIMARY TUMOR; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84893945742     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23600     Document Type: Article

References (28)

1. Noel P, Kyle RA. Plasma cell leukemia: An evaluation of response to therapy. Am J Med 1987; 83:1062-1068.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
3. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22:1044-1052.
4. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93:1032-1037.
5. Avet-Loiseau, H, Daviet, A, Brigaudeau, C, et al. Cytogenetics, interphase and multicolor fluorescence in situ hybrodization analyses in primary plasma cell leukemia: A study of 40 patients at diagnosis, on behalf of the Intergroup Francophone du Myelome and the Group Francais de Cytogenetique Hematologique. Blood 2001;97;822-825.
6. Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010;95:804-809.
7. Mahindra A, Kalaycio M, Vesole D, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012;26:1091-1097.
8. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005;78:288-294.
9. Van de Donk N, Lokhorst HM, Anderson KC, et al. How I treat plasma cell leukemia. Blood 2012;120:2376-2389.
10. Rajkumar SV. Multiple myeloma: 2013 Update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226-235.
11. Katodritou E, Verrou E, Gastari V, et al. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific vcytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 2008;32:1153-1156.
12. Lebovic D, Zhang L, Alsina M, et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: A singleinstitution experience. Clin Lymphoma Myeloma Leuk 2011;11:507-511.
13. D'Arena G, Valentini CG, Pietrantuono G, et al. Frontline chemotherapy with bortezomibcontaining combinations improves response rate and survival in primary plasma cell leukemia: A retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012;23:1499-1502.
14. Finnegan D, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukemia. Leukemia Lymphoma 2007;47:1670-1673.
15. Esparis-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005;114:665-667.
16. Libby E, Candelaria-Quintana D, Moualla H, et al. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol 2010;85:733-734.
17. De Larrea CF, Kyle RA, Durie BGM, et al. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013;27:780-791.
18. Durie BGM, Harousseau JL, Miguel JS, et al. International Uniform response criteria. Leukemia 2006;20:1467-1473.
19. Reeder GB, Reece DE, Kukreti V, et al. Once versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed Multiple Myleoma. Blood 2010;115:3416-3417.
20. Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leukemia: A surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer 2009;115:5734-5739.
21. Sher T, Miller KC, Deeb G, et al. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol 2010;150:418-427.
22. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152-1157.
23. Colović M, Janković G, Suvajdzić N, et al. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol 2008;25:154-160.
24. Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: A retrospective multicenter study of 73 patients. Ann Oncol 2011;22:1628-1635.
25. Musto P, Pagano L, Petrucci MT, et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 2011;82:141-149.
26. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Treatment strategies in relapsed and refractory multiple myeloma: A focus on drug sequencing or 'retreatment' approaches in the era of novel agents. Leukemia 2012;26:73-85.
27. Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121:884-892.
28. Mateos MV, Oriol A, Martínez-López J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol 2010;11:934-941.